News

GreyScan • January 23rd 2023

GreyScan extends its collaboration with the University of Tasmania and progresses with new product offerings for new markets

The ETD-100, a rapid mobile trace detector capable of detecting inorganic materials used in homemade explosives, was developed as part of a joint project with the University of Tasmania, and based on the research of the university’s Professor Michael Breadmore. Following on from the ETD-100’s commercialisation, GreyScan has extended its agreement with the university to expand its core technology to new applications.

The forward-thinking design of GreyScan’s Capillary Zone Electrophoresis (CZE) technology includes a core module which is then equipped with the specific chemistry and detector required for its intended purpose. Consequently, pivoting to new applications is made significantly easier due to this modular design and the product’s inherent adaptability. As a result, the same core CZE technology can be easily applied to an expanding application.

With the product’s intrinsic adaptability, the continued collaboration with UTas has led to the development and proof of concept of the Pharmaceutical Trace Detector (PTD), an innovative device designed to significantly expedite mandatory cleaning checks in therapeutic goods manufacturing. With its capability to analyse samples in less than a minute, the PTD will improve pharmaceutical manufacturing output by significantly reducing equipment idle time.

The true potential of the PTD for application in pharmaceutical cleaning verification has been substantiated by a collaborative research project undertaken by UTas, Pfizer and GreyScan, which has recently been peer reviewed and published in the highly esteemed Journal of Chromatography.

https://www.sciencedirect.com/science/article/pii/S0021967322008573

However, the possibilities of GreyScan’s core technology doesn’t stop there, with the collaboration to extend to further products and markets.

GreyScan CEO, Samantha Ollerton, said: “GreyScan is excited to be able to expand its product offering into new markets and applications that include pharmaceutical quality control and pathogen detection using the core IP platform developed in collaboration with the University of Tasmania.

“These new markets and products open up an extraordinary opportunity for GreyScan’s business growth, enabling us to take our ground-breaking products to new customer groups across the world.’’

Here’s how the University of Tasmania reported on our extended collaboration:

https://www.utas.edu.au/about/news-and-stories/articles/2022/detection-technology-has-real-world-impact